Navigation Links
Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors
Date:12/2/2013

BOSTON, Dec. 2, 2013 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Nancy Thornberry to its Board of Directors. Nancy's exceptional 34-year career at Merck demonstrates the power of her insight, innovation and ability to achieve competitively superior results in the pharmaceutical industry – particularly in diabetes. This makes an excellent match for the development and business opportunity expected with ITCA 650 (a breakthrough once- or twice-yearly GLP-1 for type 2 diabetes that is currently in Phase 3 clinical trials), as well as the Company's longer-term pipeline. Nancy's guidance and input will be of immediate benefit helping Intarcia chart the best course forward for ITCA 650 to bring the product to market and to help realize its full potential to improve treatment outcomes for appropriate patients with type 2 diabetes around the world.

"Nancy is an industry leader and icon of pharmaceutical innovation, having personally led the discovery, and subsequently the global franchise aspects, for a novel diabetes medicine and combinations that are fundamentally improving medical outcomes for type 2 diabetics around the world," said Kurt Graves, Chairman, President and CEO of Intarcia. "It's very exciting to have someone of Nancy's caliber and deep expertise in diabetes and metabolism join our Board and work shoulder-to-shoulder with us as we strive to bring our once-yearly and potentially game-changing medicine, ITCA 650, to patients suffering from type 2 diabetes. Our Board and management team are all extremely excited to have Nancy become our newest member of our Board of Directors."

Nancy Thornberry began her distinguished career at Merck Research Laboratories in 1979 as a Biochemist, and steadily assumed positions of increasing responsibility – distinguishing herself along the way with
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
2. Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
3. Scientists develop way to successfully give nanoparticle therapeutics orally
4. Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Dose-Ranging Field Study in Client-Owned Dogs with Osteoarthritis
5. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
8. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
9. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
10. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
11. Convoy Therapeutics Appoints Clinical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/11/2014)... Cayenne Medical, Inc., a privately ... soft tissue reconstruction segment, announced the worldwide launch ... involving the shoulder and extremities. The SureLock System ... deployment method. The unique delivery eliminates manual tensioning ... or anchor displacement (also commonly know as anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... Emisphere Technologies, Inc.,(Nasdaq: EMIS ), a biopharmaceutical ... therapeutic molecules using its eligen(R) technology,today announced that the ... on February 12, 2008 at the Waldorf Astoria Hotel ... Chief Executive Officer of,Emisphere, will present for the company ...
... Feb. 4 Pfizer,s loss of some top,talent, ... gain of two,Michigan companies teaming to help speed ... metastatic bone disease, rheumatoid arthritis and,osteoporosis., Velcura ... announced,his biotechnology company will work with Dr. Sliskovic ...
... Number of ... Patients, MALVERN, Pa., Feb. 4 Johns Hopkins ... in the United,States to install the newest magnetic resonance ... -- the,MAGNETOM(R) Verio. Combining 3 Tesla (T) strength and ...
Cached Biology Technology:Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12 2Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 3
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... demonstrated that transplantation of mesenchymal stem cells can stimulate ... models of Alzheimer,s disease (AD) and improve tissue and ... studies are reported on the therapeutic effect of adipose-derived ... on the effect on oxidative injury and neurogenesis in ... her team, School of Life Sciences, Tsinghua University, China ...
(Date:7/11/2014)... -- Research and Markets has announced the ... Industry Analysis Size Share Growth Trends and Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number ... for high level security in both private and public ... username and passwords, tokens etc. are vulnerable to attacks. ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... has provided new insight into the consequence of ... Prion and Alzheimer,s disease. Prion and Alzheimer,s ... mutations, or more commonly, interactions between an individual,s ... neurons to become misfolded or misrouted. In these ...
... have bacteria in their guts that may predispose them to ... University of California, Berkeley, and the University of Arizona, Tucson. ... than a thousand people from around the world showed that ... have been linked to obesity than did people living farther ...
... have shifted over the past 4 to 6 years, ... rose to the fore. Scientists who are leading advisors ... examine the state-of-the-science in "Research Challenges in Climate Change: ... 14 at the American Association for the Advancement of ...
Cached Biology News:New insight into protein misfolding in neurodegenerative disorders 2Geographic variation of human gut microbes tied to obesity 2Geographic variation of human gut microbes tied to obesity 3Hot issues in climate change research to be debated at AAAS Annual Meeting 2
... DMW143 taken from the SMZ line is a ... production and testing. It is available with a ... or a space-saving compact base (N2GG). This microscope ... and a projector all at the same time ...
... , Automatic grid, subgrid and spot finding overcome ... template assignment , ... Extensive background and signal options to optimize, ... results , Characterize more precisely ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... contains 400 unique human proteins on ... The proteins, a cross section of ... quadruplicate for high-quality results. Additional control ... guarantee high validity and reproducibility., ,UNIchip ...
Biology Products: